Quick Answer
Akebia Therapeutics, Inc. reported Operating Income Loss of $23.50 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +146.6% in Operating Income Loss from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: -$7.84 million | Q3 2014: -$9.58 million | Q4 2014: -$10.61 million | Q1 2015: -$10.90 million | Q2 2015: -$10.89 million | Q3 2015: -$19.68 million | Q4 2015: -$20.05 million | Q1 2016: -$26.05 million | Q2 2016: -$36.19 million | Q3 2016: -$36.18 million | Q4 2016: -$38.04 million | Q1 2017: -$44.97 million | Q2 2017: -$22.14 million | Q3 2017: -$24.18 million | Q4 2017: $14.61 million | Q1 2018: -$24.50 million | Q2 2018: -$35.66 million | Q3 2018: -$27.84 million | Q4 2018: -$90.16 million | Q1 2019: -$75.97 million | Q2 2019: -$59.52 million | Q3 2019: -$55.91 million | Q4 2019: -$94.89 million | Q1 2020: -$59.13 million | Q2 2020: -$173.82 million | Q3 2020: -$58.10 million | Q4 2020: -$85.40 million | Q1 2021: -$64.94 million | Q2 2021: -$79.34 million | Q3 2021: -$54.89 million | Q1 2022: -$59.58 million | Q2 2022: $34.08 million | Q3 2022: -$50.41 million | Q1 2023: -$25.60 million | Q2 2023: -$9.00 million | Q3 2023: -$13.04 million | Q1 2024: -$14.94 million | Q2 2024: -$8.73 million | Q3 2024: -$12.51 million | Q1 2025: $13.51 million | Q2 2025: $14.09 million | Q3 2025: $4.45 million.
- Over the full 14 years of available data (2012 to 2025), Akebia Therapeutics, Inc.'s Operating Income Loss has grown by 375.7%.
- Historical annual values: Fiscal year 2025: $23.50 million | Fiscal year 2024: -$50.47 million | Fiscal year 2023: -$46.26 million | Fiscal year 2022: -$80.78 million | Fiscal year 2021: -$265.32 million | Fiscal year 2020: -$376.44 million | Fiscal year 2019: -$286.29 million | Fiscal year 2018: -$178.16 million | Fiscal year 2017: -$76.67 million | Fiscal year 2016: -$136.46 million | Fiscal year 2015: -$61.51 million | Fiscal year 2014: -$37.94 million | Fiscal year 2013: -$15.93 million | Fiscal year 2012: -$8.52 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: